Concepedia

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

Luis Rivera, Shibadas Biswal, Xavier Sáez‐Llorens, Humberto Reynales, Eduardo López‐Medina, Charissa Borja-Tabora, Lulu Bravo, Chukiat Sirivichayakul, Pope Kosalaraksa, Luis Martinez Vargas,

Clinical Infectious Diseases · 2021 · 226 citations · 17 references

DOIFull text

Open access

Abstract

TAK-003 was efficacious against symptomatic dengue over 3 years. Efficacy declined over time but remained robust against hospitalized dengue. A booster dose evaluation is planned.

References

17

The global distribution and burden of dengue

Samir Bhatt, Peter W. Gething, Oliver J. Brady et al. · Nature · 2013 · 9.8K citations · Full text

, , +4

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

Saranya Sridhar, Alexander R. Luedtke, Edith Langevin et al. · New England Journal of Medicine · 2018 · 756 citations · Full text

Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

Shibadas Biswal, Humberto Reynales, Xavier Sáez‐Llorens et al. · New England Journal of Medicine · 2019 · 357 citations · Full text

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

Shibadas Biswal, Charissa Borja-Tabora, Luis Martinez Vargas et al. · The Lancet · 2020 · 237 citations

, , +5

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

Jorge E. Osorio, Iván Darío Vélez, Cynthia A. Thomson et al. · The Lancet Infectious Diseases · 2014 · 149 citations · Full text

, , +9